-
公开(公告)号:US20230374370A1
公开(公告)日:2023-11-23
申请号:US18364526
申请日:2023-08-03
IPC分类号: C09K8/54 , C07D239/04 , C23F11/14 , E21B41/02
CPC分类号: C09K8/54 , C07D239/04 , C23F11/149 , E21B41/02 , C09K2208/32
摘要: Compositions may include a corrosion inhibitor including a heterocyclic diamine prepared from the reaction of an alkyl diamine and an aldehyde, wherein the alkyl diamine has the general formula: R4NH(CH2)nNHR5, where n is an integer between 3 and 6, and R4 and R5 are independently hydrogen or a C2-C30 saturated or unsaturated hydrocarbon radical. Methods may include contacting a metal surface with a corrosion inhibitor composition, wherein the corrosion inhibitor includes a heterocyclic diamine corrosion inhibitor from the reaction of an alkyl diamine and an aldehyde, wherein the alkyl diamine has the general formula: R4NH(CH2)nNHR5, where n is an integer between 3 and 6, and R4 and R5 are independently hydrogen or a C2-C30 saturated or unsaturated hydrocarbon radical.
-
公开(公告)号:US11695157B2
公开(公告)日:2023-07-04
申请号:US17583240
申请日:2022-01-25
发明人: Tiancheng Yi , Chunhua Hu , Shushi Dou , Yao Jiang , Chengdu Liang
IPC分类号: H01M10/0567 , C01G51/00 , C07D239/04 , C07D241/04 , C07D251/04 , C07D295/145 , C07D403/04 , H01M4/525 , H01M10/0525 , H01M10/42 , H01M10/0568 , H01M4/02
CPC分类号: H01M10/0567 , C01G51/006 , C01G51/42 , C07D239/04 , C07D241/04 , C07D251/04 , C07D295/145 , C07D403/04 , H01M4/525 , H01M10/0525 , H01M10/0568 , H01M10/4235 , C01P2002/52 , C01P2006/40 , H01M2004/028 , H01M2300/0025
摘要: This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Lix1Coy1M1-y1O2-z1Qz1, where 0.5≤x1≤1.2, 0.8≤y1≤1.0, 0≤z1≤0.1, M is selected from one or more of Al, Ti, Zr, Y, and Mg, and Q is selected from one or more of F, Cl, and S. The electrolyte contains an additive A that is a polynitrile six-membered nitrogen-heterocyclic compound with a relatively low oxidation potential. The lithium-ion battery has superb cycle performance and storage performance, especially under high-temperature and high-voltage conditions.
-
公开(公告)号:US20220209296A1
公开(公告)日:2022-06-30
申请号:US17697265
申请日:2022-03-17
发明人: Tiancheng YI , Chunhua HU , Yao JIANG , Shushi DOU , Chengdu LIANG
IPC分类号: H01M10/0567 , C07D239/04 , C07D241/04 , C07D251/04 , C07D295/15 , C07D403/04 , H01M4/525 , H01M10/0525 , H01M10/0569
摘要: The present application provides a lithium-ion battery and an apparatus, and the lithium-ion battery includes an electrode assembly and an electrolytic solution, the electrode assembly includes a positive electrode sheet, a negative electrode sheet and a separation film. A positive active material of the positive electrode sheet includes Lix1Coy1M1-y1O2-z1Qz1, 0.5≤x1≤1.2, 0.85≤y1≤1.0, 0≤z1≤0.1 M is selected from one or more of Al, Ti, Zr, Y, and Mg, and Q is selected from one or more of F, Cl, and S. The electrolytic solution contains vinylene carbonate, fluoroethylene carbonate, 1,3-propane sultone, and an additive A. The additive A is a polynitrile six-membered nitrogen-heterocyclic compound with a relatively low oxidation potential. The lithium-ion battery has superb cycle performance and storage performance, especially under high-temperature and high-voltage conditions.
-
公开(公告)号:US11239500B2
公开(公告)日:2022-02-01
申请号:US17056740
申请日:2019-12-13
发明人: Shushi Dou , Chunhua Hu , Tiancheng Yi , Yao Jiang , Chengdu Liang
IPC分类号: H01M10/0567 , C07D239/04 , C07D251/04 , C07F9/09 , C07F9/141 , H01M4/36 , H01M4/38 , H01M4/48 , H01M4/525 , H01M4/587 , H01M10/0525
摘要: This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Lix1Coy1M1-y1O2-z1Qz1, where 0.5≤x1≤1.2, 0.8≤y1
-
公开(公告)号:US20210238469A1
公开(公告)日:2021-08-05
申请号:US17053857
申请日:2019-05-08
IPC分类号: C09K8/54 , C07D239/04 , E21B41/02 , C23F11/14
摘要: Compositions may include a corrosion inhibitor including a heterocyclic diamine prepared from the reaction of an alkyl diamine and an aldehyde, wherein the alkyl diamine has the general formula: R4NH(CH2)nNHR5, where n is an integer between 3 and 6, and R4 and R5 are independently hydrogen or a C2-C30 saturated or unsaturated hydrocarbon radical. Methods may include contacting a metal surface with a corrosion inhibitor composition, wherein the corrosion inhibitor includes a heterocyclic diamine corrosion inhibitor from the reaction of an alkyl diamine and an aldehyde, wherein the alkyl diamine has the general formula: R4NH(CH2)nNHR5, where n is an integer between 3 and 6, and R4 and R5 are independently hydrogen or a C2-C30 saturated or unsaturated hydrocarbon radical.
-
公开(公告)号:US10938068B2
公开(公告)日:2021-03-02
申请号:US17043683
申请日:2019-12-13
发明人: Yao Jiang , Chunhua Hu , Tiancheng Yi , Shushi Dou , Chengdu Liang
IPC分类号: H01M10/05 , H01M4/52 , C07D239/04 , C07D251/04 , H01M10/0567 , H01M10/0525 , H01M4/525 , C07D241/04 , H01M4/02
摘要: This application provides a lithium-ion battery and an apparatus. The lithium-ion battery includes an electrode assembly and an electrolyte. The electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator. A positive active material of the positive electrode plate includes Lix1Coy1M1-y1O2-z1Qz1, where 0.5≤x1≤1.2, 0.8≤y1
-
7.
公开(公告)号:US20190185457A1
公开(公告)日:2019-06-20
申请号:US16220031
申请日:2018-12-14
发明人: Shiro IRISA , Keisuke KORAI , Mitsunori ITO
IPC分类号: C07D403/10 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D471/04 , C07D239/04 , C07D495/04 , H01L51/00 , H01L51/50
CPC分类号: C07D403/10 , C07D239/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D471/04 , C07D495/04 , H01L51/0034 , H01L51/0058 , H01L51/006 , H01L51/0067 , H01L51/0072 , H01L51/0073 , H01L51/0074 , H01L51/5016 , H01L51/5056 , H01L51/5072 , H01L51/5092 , H01L51/5096
摘要: A heterocyclic compound represented by Formula 1: (A)n-L, Formula 1 wherein, in Formula 1, A, L, and n are the same as described in the specification.
-
公开(公告)号:US09682928B2
公开(公告)日:2017-06-20
申请号:US14472181
申请日:2014-08-28
IPC分类号: C07D295/084 , C07C311/39 , A61K31/4355 , C07D211/44 , C07D231/04 , C07D233/02 , C07D237/02 , C07D239/04 , C07D241/04 , C07D261/02 , C07D263/04 , C07D265/30 , C07D275/02 , C07D277/04 , C07D279/12 , C07D307/52
CPC分类号: A61K31/18 , A61K31/4355 , C07C311/39 , C07D211/44 , C07D231/04 , C07D233/02 , C07D237/02 , C07D239/04 , C07D241/04 , C07D261/02 , C07D263/04 , C07D265/30 , C07D275/02 , C07D277/04 , C07D279/12 , C07D295/084 , C07D307/52
摘要: The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl− co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.
-
公开(公告)号:US08618103B2
公开(公告)日:2013-12-31
申请号:US12878048
申请日:2010-09-09
申请人: Javier de Vicente Fidalgo , Johannes Cornelius Hermann , Remy Lemoine , Hongju Li , Allen John Lovey , Eric Brian Sjogren , Michael Soth
发明人: Javier de Vicente Fidalgo , Johannes Cornelius Hermann , Remy Lemoine , Hongju Li , Allen John Lovey , Eric Brian Sjogren , Michael Soth
IPC分类号: C07D487/04 , A61K31/4985 , C07D239/04 , A61K31/506 , A61P29/00 , A61P35/00
CPC分类号: C07D487/04 , C07D513/04
摘要: The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.
摘要翻译: 本发明涉及式I的新化合物的用途,其中变量m,n,p,q,Q,r,R,R',X,X',Y,Z 1,Z 2和Z 3定义为 其抑制JAK并且可用于治疗自身免疫和炎性疾病。
-
公开(公告)号:US08299063B2
公开(公告)日:2012-10-30
申请号:US12920774
申请日:2009-03-13
申请人: Scott Peter Webster , Jonathan Robert Seckl , Brian Robert Walker , Peter Ward , Thomas David Pallin , Hazel Joan Dyke , Trevor Robert Perrior
发明人: Scott Peter Webster , Jonathan Robert Seckl , Brian Robert Walker , Peter Ward , Thomas David Pallin , Hazel Joan Dyke , Trevor Robert Perrior
IPC分类号: A61K31/55 , A61K31/551 , A61K31/541 , A61K31/5355 , A61K31/536 , A61K31/496 , A61K31/498 , A61K31/4709 , A61K31/451 , A61K31/4535 , A61K31/4402 , A61K31/4155 , C07D243/08 , C07D401/14 , C07D403/14 , C07D265/36 , C07D265/30 , C07D279/12 , C07D231/12 , C07D239/04
CPC分类号: C07D409/06 , C07D409/14 , C07D413/06 , C07D413/14 , C07D487/04 , C07D487/08
摘要: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
摘要翻译: 本发明一般涉及治疗化合物领域。 更具体地说,本发明涉及某些特别是抑制11型β-羟基类固醇脱氢酶(11& bgr-HSD1)的酰氨基噻吩化合物。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在体外和体内的用途,以抑制1型的1β-羟基类固醇脱氢酶; 治疗通过抑制11型β-羟基类固醇脱氢酶1改善的病症; 治疗代谢综合征,其包括诸如2型糖尿病和肥胖症的疾病,以及包括胰岛素抵抗,高血压,脂质障碍和心血管疾病如缺血性(冠心病)心脏病的相关疾病; 治疗CNS疾病如轻度认知障碍和早期痴呆,包括阿尔茨海默氏病; 等等
-
-
-
-
-
-
-
-
-